Show simple item record

dc.contributor.advisorTabrejee, Shamira
dc.contributor.authorMondol, Winifred Claire
dc.date.accessioned2018-10-17T05:20:23Z
dc.date.available2018-10-17T05:20:23Z
dc.date.copyright2018
dc.date.issued2018-09
dc.identifier.otherID 14136009
dc.identifier.urihttp://hdl.handle.net/10361/10721
dc.descriptionThis thesis is submitted in partial fulfilment of the requirements for the degree of Bachelor of Science in Biotechnology, 2018.en_US
dc.descriptionCataloged from PDF version of thesis.
dc.descriptionIncludes bibliographical references (page 51-57).
dc.description.abstractMycobacterium tuberculosis is an obligate pathogenic bacterial species in the family Mycobacteriaceae and the causative agent of tuberculosis. At present BCG, an attenuated strain of Mycobacterium bovis is used as a vaccine against tuberculosis. However, the overall success of BCG is arguable as it has some serious limitations. Some of these include BCG’s inability to protect against TB in adults and also in immunosuppressed patients. Thus, it is necessary to develop vaccines that can replace BCG. In this study, various computational methods were employed to identify T-cell epitopes from the ESX-2 secretion-associated protein EspG2, which has the potential for vaccine development against Mycobacterium tuberculosis. After analyzing the immune parameters of ESX-2 secretion-associated protein EspG2 using various databases and bioinformatics tools which included IEBD, PEP-FOLD, PyRx, PyMol, etc. One T cell epitope was identified which may be used as epitope-based peptide vaccine. Five highly conserved, non- allergenic, non-cytotoxic putative T-cell epitopes were analyzed for their binding with the HLA-C 12*03 molecule. Amongst them one epitope was chosen which interacted with the maximum number of MHC alleles with satisfactory world population coverage. Docking simulation assay further revealed that SGQRRYQVL has significantly lower binding energy, which verifies that the binding cleft epitope interaction to HLA molecule will occur when it will be applied in vivo. Additional in vivo investigation can further provide concrete evidence that SGQRRYQVL be used as a peptide vaccine to effectively promote immunity against TB.en_US
dc.description.statementofresponsibilityWinifred Claire Mondol
dc.format.extent57 pages
dc.language.isoenen_US
dc.publisherBRAC Universityen_US
dc.rightsBRAC University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectMycobacterium tuberculosisen_US
dc.subjectIn silico T-cellen_US
dc.subject.lcshMycobacterium tuberculosis -- immunology
dc.subject.lcshTuberculosis -- immunology
dc.titleIn silico T-cell epitopebased vaccine designing against Mycobacterium tuberculosisen_US
dc.typeThesisen_US
dc.contributor.departmentDepartment of Mathematics and Natural Sciences, BRAC University
dc.description.degreeB. Biotechnology


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record